Zenith Epigenetics:
file:///C:/Users/George/Downloads/Triple_Negative_
Breast_Cancer_Drug_Development___Brochure.pdf
Eric Campeau Senior Director - Translational Medicine Zenith Epigenetics
Thursday, April 29, 2021, 4 PM EST
Phase 1b/2 Combination Study of the BET Inhibitor ZEN-3694 with the PARP Inhibitor Talazoparib for the Treatment of TNBC Patients without gBRCA1/2 Mutations
-PARP inhibitor activity is limited to tumors with BRCA1 or BRCA2 or PALB2 mutations in TNBC patients
-Preclinical models have shown that BET bromodomain inhibitors sensitize tumors to PARP inhibitors regardless of BRCA status
- ZEN-3694 + talazoparib combination is well tolerated and has shown clinical activity in TNBC patients without germline BRCA1/2 mutations (or PALB2)
Koo
